News & Press

CEO Discusses CDMO Capex Growth & Expansion in 2022

Edition 1 / March 2022
CEO Editorial > 2022 & Beyond: Resiliency, Expansion & Growth

Edition 1 / March 2022

Dr. Michael Quirmbach President & CEO CordenPharma Group, headshot

Dr. Michael Quirmbach

President & CEO

2022 & Beyond: Resiliency, Expansion & Growth

Welcome to the first 2022 quarterly edition of Corden Connect. Now in our 4th year of publishing this newsletter, it’s hard to believe we have almost passed the first quarter of 2022! With the year off to another good start, I would like to begin by saying THANK YOU to our existing & new customers for all the collaboration, ongoing trust and loyalty you placed with us in 2021.

As I reflect back on the past year, 2021 was an exciting time for CordenPharma in a number of key areas. Not only did the team deliver exceptional growth across our global network, which resulted in sales of > €750 M for the first time in our 15-year history, but we also proudly maintained business continuity for many customers and patients by delivering critical medications on time and in full, despite the continuing global pandemic circumstances. I am very proud of the excellent teams in our manufacturing sites across Europe and the United States for their exceptional commitment, strong performance and dedication demonstrated last year.

A major highlight of 2021 was the kick-off of the largest Strategic CAPEX Program since CordenPharma’s inception, as part of the long-term 5 Year Group Strategic Business Plan (SBP). Key projects include:

  • >> Technology entry into Lipid Nanoparticle Formulation (LNP) at CordenPharma Caponago (IT), together with Wacker Biotech
  • >> Large expansion & renewal program at CordenPharma Chenôve (FR), including technology enhancement in new areas such as Supercritical Fluid Chromatography (SFC) & Continuous Manufacturing.
  • >> Final build-out of the Small Molecule Development Center at CordenPharma Switzerland (Liestal, CH), and establishment of a Solid-State Centre of Excellence.
  • >> Expansion & construction of a new Highly Potent Oral Solid Dosage (OSD) development capacity at CordenPharma Plankstadt (DE), including capsule filling technology.
  • >> Construction of new development labs at CordenPharma Bergamo (IT).
  • >> Expansion of our service offerings in CordenPharma Frankfurt (DE) with new small-scale cGMP capacity for manufacturing Peptides for Phases I – II.

As 2021 was a major milestone in our young history, another highlight was our 15 Year Anniversary global celebration that took place simultaneously at each site on October 1, 2022. This was an important moment to acknowledge CordenPharma’s transition and growth from a number of acquired pharma sites with diverse backgrounds into a world-class, industry-leading CDMO offering APIs, Excipients and Drug Products. In the last seven years alone, we have grown from a € 250 M company with about 1,000 employees to become one of today’s fastest growing CDMOs with over 2,600 employees. Our journey of turning a legacy portfolio of products and processes into an integrated network has not been without its challenges, but our collective efforts to bring new customers, projects & products has resulted in a new dimension of flexibility, agility and strong Customer Centricity. Thank you to all our customers who have continued to entrust us with their key projects over the years!

Finally, in December 2021 we announced the acquisition of three drug product sites from Vifor Pharma (which was completed on January 31, 2022). With the new manufacturing facilities, we were able to successfully increase our capacity and close gaps in our service offerings for Oral Solid Dosage (OSD) drug product development and manufacturing, allowing us to further strengthen our end-to-end solutions for customers. The addition of the new facilities resulted in a total workforce of more than 2,600 employees, comprising a global network of eleven manufacturing sites and one R&D center, and total projected sales of greater than €850 M starting in 2022. Below Dr. Stephen Houldsworth conducts a video interview with Yvan Liard, the new Managing Director of the recently-acquired CordenPharma Fribourg & Ettingen sites, and later discusses in his article the expansion of our Small Molecules platform with the addition of new OSD and other specialty dosage drug product forms in CordenPharma Lisbon as well.

With all these strategic initiatives across CordenPharma, we continue our aim in better serving our customers and their patients by identifying and expanding on key trends & technologies in the pharmaceutical industry that contribute towards the development of innovative life-saving medications. I can assure you that the CordenPharma team continues to be inspired by the direct impact our customers have on patients, and as such, we strive for excellence every day to deliver on-time, high-quality products with integrity, transparency and flexibility.

As we embark on this new year, we continue to focus our growth on five key Technology Platforms: Peptides, Lipids & Carbohydrates, Highly Potent & Oncology, Small Molecules, and Injectables. In addition, we will strengthen our Fully Integrated Supply Solutions (API Starting Materials > Intermediates > APIs & Excipients > Drug Products > Packaging) to bring you the maximum benefit for this increased demand.

We look forward to finally meeting customers in person this year at the upcoming DCAT Week – March 21 – 24 in New York City – or any other planned trade shows to discuss your ongoing & future project needs.

To conclude, feel free to reach out to your respective Key Account Managers to schedule a meeting or provide any feedback on how you believe we can better serve you in the future! We look forward to a successful 2022!

Dr. Michael Quirmbach
President & CEO, CordenPharma

Subscribe to our Newsletter

Stay up to date with the latest thought leadership articles and news from CordenPharma.